Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 65 Researches
7.5
USERS' SCORE
Good
Based on 13 Reviews
8.4
Supplement Facts
Serving Size: 1 Capsule
Amount Per Serving
%DV
Colon Care BlendBifidobacterium lactis BL818, Lactobacillus acidophilus (SD-5221), Bifidobacterium lactis (SD-5674), Raw Whole Food Probiotic Blend: Bulgarian Yogurt (milk) Concentrate, ^Eastern European Wild Kefir Culture containing Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus kefiranofaciens, Lactobacillus kefirgranum, Lactobacillus rhamnosus, Lactococcus lactis, Lactococcus cremoris, Streptococcus thermophilus, Lactobacillus kefir, Lactobacillus parakefir, Lactobacillus plantarum, Lactococcus lactis biovar diacetylactis, Leuconostoc lactis, Leuconostoc mesenteroides, Leuconostoc cremoris, Leuconostoc dextranicum, Kluyveromyces marxianus, Brettanomyces anomalus, Debaryomyces hansenii, Saccharomyces unisporus, Saccharomyces turicensis, Saccharomyces cerevisiae, Saccharomyces exiguus, Torulaspora delbrueckii
50 Billion CFU¹
+
Colon Transit Support Enzyme BlendAmylase, Protease, Lactase, Glucoamylase, alpha-Galactosidase, Lipase, Pectinase, Peptidase, Bromelain, Phytase, Hemicellulase, beta-Glucanase, Papain, Cellulase, Xylanase, Diastase, Invertase
50 mg
+
Eastern European Raw Fruit & Veggie BlendRed Bell Pepper (Fruit), Green Pea (Seed), Carrot (Root), Plum (Fruit), Cherry (Fruit), Strawberry (Fruit), Raspberry (Fruit)
45 mg
+
Top Medical Research Studies
A randomized, double-blind, placebo-controlled trial exploring CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) revealed promising results for diarrhea-predominant irritable bowel syndrome (IBS-D).
We found that after 12 weeks, both ES1 and HT-ES1 significantly reduced symptom severity compared to a placebo, as shown by lower IBS-Symptom Severity Scale scores.
Other improvements included better stool consistency and quality of life. This study marks a breakthrough with the first positive findings for a probiotic or postbiotic from this strain specifically for IBS-D patients.
We found that after 12 weeks, both ES1 and HT-ES1 significantly reduced symptom severity compared to a placebo, as shown by lower IBS-Symptom Severity Scale scores.
Other improvements included better stool consistency and quality of life. This study marks a breakthrough with the first positive findings for a probiotic or postbiotic from this strain specifically for IBS-D patients.
Read More
9.5
We explored how Saccharomyces cerevisiae affects patients with irritable bowel syndrome (IBS). In a study involving thirty participants, we administered 500 mg capsules of this yeast twice daily for four weeks. Weekly evaluations showed significant improvements in abdominal pain and general quality of life, with notable reductions in pain scores and enhancements in various aspects of daily living. This suggests Saccharomyces cerevisiae could be a valuable treatment option for alleviating IBS symptoms.
Read More
9
We aimed to understand how Lacticaseibacillus rhamnosus IDCC 3201 (RH 3201) affects irritable bowel syndrome with constipation (IBS-C) through a thorough study. In a randomized, double-blind trial, 30 participants took either RH 3201 or a placebo for 8 weeks.
Those taking RH 3201 experienced significant improvements, including fewer bowel discomforts and reduced bloating issues. We also observed an increase in certain beneficial gut bacteria and a link between specific metabolites and symptom relief. Overall, RH 3201 shows promise as an effective treatment for IBS-C.
Those taking RH 3201 experienced significant improvements, including fewer bowel discomforts and reduced bloating issues. We also observed an increase in certain beneficial gut bacteria and a link between specific metabolites and symptom relief. Overall, RH 3201 shows promise as an effective treatment for IBS-C.
Read More
Most Useful Reviews
10
Life-changing
6 people found this helpful
For three years, I frequently dealt with digestive issues, including irritable bowel syndrome and constipation. Following a week in the hospital, my doctor recommended probiotics, leading me to this brand. I've tried other products from them before and found them to be excellent quality. I’m now on my fifth bottle, and my stomach feels great. I wholeheartedly recommend you try them—you won’t regret it!
Read More
9
Digestive problem solved
1 people found this helpful
The quality of ingredients in this product is excellent, and the capsule size suits us well, as we regularly take supplements at home. We’ve all benefitted from these probiotics, with my daughter resolving her irritable bowel issue, and my digestive problems improving significantly. We’ve decided to take it annually to maintain gut health, as the benefits are substantial. We received the package quickly, exceeding our expectations. Thank you, iHerb!
Read More
9
Frequent bowel movements
I'm truly hooked on this probiotic! I’ve been taking it for around six months and even introduced it to my mother. I used to suffer from severe constipation and irritable bowel syndrome symptoms. Within a month, my bowel movements became more frequent and the symptoms of IBS lessened. I've purchased it multiple times, as it's an effective probiotic that genuinely works.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 65 Researches
7.5
- All Researches
9.5
This randomized, single-blinded trial evaluated the impact of probiotics, specifically Lactobacillus acidophilus and plantarum, on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.
Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.
Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
Read More
9.5
This randomized, single-blinded trial evaluated the impact of probiotics, specifically Lactobacillus acidophilus and plantarum, on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.
Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.
Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
Read More
A randomized, double-blind, placebo-controlled trial exploring CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) revealed promising results for diarrhea-predominant irritable bowel syndrome (IBS-D).
We found that after 12 weeks, both ES1 and HT-ES1 significantly reduced symptom severity compared to a placebo, as shown by lower IBS-Symptom Severity Scale scores.
Other improvements included better stool consistency and quality of life. This study marks a breakthrough with the first positive findings for a probiotic or postbiotic from this strain specifically for IBS-D patients.
We found that after 12 weeks, both ES1 and HT-ES1 significantly reduced symptom severity compared to a placebo, as shown by lower IBS-Symptom Severity Scale scores.
Other improvements included better stool consistency and quality of life. This study marks a breakthrough with the first positive findings for a probiotic or postbiotic from this strain specifically for IBS-D patients.
Read More
9.5
We explored how Saccharomyces cerevisiae affects patients with irritable bowel syndrome (IBS). In a study involving thirty participants, we administered 500 mg capsules of this yeast twice daily for four weeks. Weekly evaluations showed significant improvements in abdominal pain and general quality of life, with notable reductions in pain scores and enhancements in various aspects of daily living. This suggests Saccharomyces cerevisiae could be a valuable treatment option for alleviating IBS symptoms.
Read More
9
Lactobacillus drink benefits IBS-C
We explored the impact of a Lactobacillus-containing cultured milk drink on individuals with constipation-predominant irritable bowel syndrome (IBS-C). Over 30 days, participants consumed this drink daily while we assessed their clinical symptoms and inflammatory markers.
Impressively, 97.4% reported improvement in symptoms, along with noticeable reductions in intestinal transit time and fecal pH. Evidence also showed lowered levels of pro-inflammatory cytokines in IBS-C participants, supporting potential adjunctive benefits of this treatment for IBS-C patients.
Impressively, 97.4% reported improvement in symptoms, along with noticeable reductions in intestinal transit time and fecal pH. Evidence also showed lowered levels of pro-inflammatory cytokines in IBS-C participants, supporting potential adjunctive benefits of this treatment for IBS-C patients.
Read More
User Reviews
USERS' SCORE
Good
Based on 13 Reviews
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
10
Life-changing
6 people found this helpful
For three years, I frequently dealt with digestive issues, including irritable bowel syndrome and constipation. Following a week in the hospital, my doctor recommended probiotics, leading me to this brand. I've tried other products from them before and found them to be excellent quality. I’m now on my fifth bottle, and my stomach feels great. I wholeheartedly recommend you try them—you won’t regret it!
Read More
9
Digestive problem solved
1 people found this helpful
The quality of ingredients in this product is excellent, and the capsule size suits us well, as we regularly take supplements at home. We’ve all benefitted from these probiotics, with my daughter resolving her irritable bowel issue, and my digestive problems improving significantly. We’ve decided to take it annually to maintain gut health, as the benefits are substantial. We received the package quickly, exceeding our expectations. Thank you, iHerb!
Read More
9
Frequent bowel movements
I'm truly hooked on this probiotic! I’ve been taking it for around six months and even introduced it to my mother. I used to suffer from severe constipation and irritable bowel syndrome symptoms. Within a month, my bowel movements became more frequent and the symptoms of IBS lessened. I've purchased it multiple times, as it's an effective probiotic that genuinely works.
Read More
9
Good bowel movement
This product contains up to 33 different bacteria. I take one tablet in the morning on an empty stomach, ensuring a good bowel movement every day.
Read More
7.5
Healthy movement
1 people found this helpful
My usual bowel movements were irregular, with more gas and less solid stool. However, after using this product, I experienced reduced flatulence and healthier bowel movements. I have continued to repurchase and recommend it to family, who also say it works well.
Read More
Frequently Asked Questions
9
Frequent bowel movements
I'm truly hooked on this probiotic! I’ve been taking it for around six months and even introduced it to my mother. I used to suffer from severe constipation and irritable bowel syndrome symptoms. Within a month, my bowel movements became more frequent and the symptoms of IBS lessened. I've purchased it multiple times, as it's an effective probiotic that genuinely works.
9
Digestive problem solved
1 people found this helpful
The quality of ingredients in this product is excellent, and the capsule size suits us well, as we regularly take supplements at home. We’ve all benefitted from these probiotics, with my daughter resolving her irritable bowel issue, and my digestive problems improving significantly. We’ve decided to take it annually to maintain gut health, as the benefits are substantial. We received the package quickly, exceeding our expectations. Thank you, iHerb!
10
Life-changing
6 people found this helpful
For three years, I frequently dealt with digestive issues, including irritable bowel syndrome and constipation. Following a week in the hospital, my doctor recommended probiotics, leading me to this brand. I've tried other products from them before and found them to be excellent quality. I’m now on my fifth bottle, and my stomach feels great. I wholeheartedly recommend you try them—you won’t regret it!
7.5
Healthy movement
1 people found this helpful
My usual bowel movements were irregular, with more gas and less solid stool. However, after using this product, I experienced reduced flatulence and healthier bowel movements. I have continued to repurchase and recommend it to family, who also say it works well.
7.5
Improved movement
2 people found this helpful
I purchased this for my child to aid in detoxification. The more CFUs and strains, the better. After completing the detox program, he experienced better bowel movements, and he seems happier overall. Happy guts lead to a happy brain. Although it is somewhat costly, the quality is excellent, and I plan to repurchase when it's on discount. He is currently taking 30 billion CFUs.
9
Good bowel movement
This product contains up to 33 different bacteria. I take one tablet in the morning on an empty stomach, ensuring a good bowel movement every day.
9.5
This randomized, single-blinded trial evaluated the impact of probiotics, specifically Lactobacillus acidophilus and plantarum, on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.
Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.
Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
8
Lactobacillus acidophilus improves IBS
We aimed to investigate how well the probiotic Neobiotic Lactobalance®, which contains Lactobacillus acidophilus, can relieve symptoms of irritable bowel syndrome with diarrhea and antibiotic-associated diarrhea. Over 21 days, 54 participants took one capsule daily. With clear signs of symptom relief, patients reported significant improvements in diarrhea, abdominal pain, and dyspeptic symptoms. Our findings showed a normalization of the intestinal microbiota, indicating that Lactobacillus acidophilus and other included probiotics may effectively support digestive health for those struggling with these conditions.
8
We investigated the impact of multispecies probiotics, including Lactobacillus acidophilus, in treating irritable bowel syndrome (IBS). In a randomized, double-blind study with 49 participants, those taking probiotics experienced significantly more symptom relief than those on a placebo after four weeks.
The probiotics not only eased abdominal discomfort and bloating but also positively altered gut bacteria. Our findings suggest that multispecies probiotics could be a valuable option for managing IBS symptoms.
The probiotics not only eased abdominal discomfort and bloating but also positively altered gut bacteria. Our findings suggest that multispecies probiotics could be a valuable option for managing IBS symptoms.
This randomized double-blind placebo-controlled trial investigated how a synbiotic preparation affects adults with diarrhea-predominant irritable bowel syndrome (IBS-D).
Over eight weeks, we found that the synbiotics significantly improved overall IBS symptoms and specific issues like flatulence and bowel habits compared to the placebo.
Participants reported less discomfort such as incomplete bowel movements and fewer diarrheal episodes.
Importantly, the synbiotics were well tolerated, with no significant differences in adverse events between the groups.
Over eight weeks, we found that the synbiotics significantly improved overall IBS symptoms and specific issues like flatulence and bowel habits compared to the placebo.
Participants reported less discomfort such as incomplete bowel movements and fewer diarrheal episodes.
Importantly, the synbiotics were well tolerated, with no significant differences in adverse events between the groups.
References
- Sarkawi M, Raja Ali RA, Abdul Wahab N, Abdul Rathi ND, Mokhtar NM. A randomized, double-blinded, placebo-controlled clinical trial on Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in irritable bowel syndrome. Sci Rep. 2024;14:9478. doi:10.1038/s41598-024-60029-2
- Shanshal SA, Alsaaty MH, Al-Qazaz H, Al-Zidan RN. Two Lactobacilli strains as adjuvant therapy in the management of irritable bowel syndrome: a randomized control trial. Ceska Slov Farm. 2024;72:233.
- Shanshal SA, Alsaaty MH, Al-Qazaz H, Al-Zidan RN. Two Lactobacilli strains as adjuvant therapy in the management of irritable bowel syndrome: a randomized control trial. Ceska Slov Farm. 2024;73:233.
- Chang YH, Choi YJ, Shin CM, Moon JS, Kim TY, et al. Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. J Neurogastroenterol Motil. 2024;30:73. doi:10.5056/jnm23036
- Drozdov VN, Shikh EV, Astapovskii AA, Khalaidzheva KN, Solovieva SA, et al. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea and antibiotic-associated diarrhea]. Vopr Pitan. 2023;92:92. doi:10.33029/0042-8833-2023-92-4-92-103
- Cocetta V, Giacomini I, Tinazzi M, Berretta M, Quagliariello V, et al. Maintenance of intestinal epithelial barrier integrity by a combination of probiotics, herbal extract, and vitamins. Minerva Pediatr (Torino). 2023. doi:10.23736/S2724-5276.23.07128-8
- Shin SY, Park S, Moon JM, Kim K, Kim JW, et al. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial. J Neurogastroenterol Motil. 2022;28:642. doi:10.5056/jnm21202
- Mokhtar NM, Jaafar NM, Alfian E, Mohd Rathi ND, Abdul Rani R, et al. Clinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink. Acta Gastroenterol Belg. 2021;84:585. doi:10.51821/84.4.009
- Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, et al. The Effectiveness of Synbiotic Preparation Containing and Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study. Nutrients. 2020;12. doi:10.3390/nu12071999
- Martoni CJ, Srivastava S, Leyer GJ. DDS-1 and UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. 2020;12. doi:10.3390/nu12020363
- Sadrin S, Sennoune S, Gout B, Marque S, Moreau J, et al. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liver Dis. 2020;52:534. doi:10.1016/j.dld.2019.12.009
- Preston K, Krumian R, Hattner J, de Montigny D, Stewart M, et al. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Benef Microbes. 2018;9:697. doi:10.3920/BM2017.0105
- Leventogiannis K, Gkolfakis P, Spithakis G, Tsatali A, Pistiki A, et al. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. Probiotics Antimicrob Proteins. 2019;11:627. doi:10.1007/s12602-018-9401-3
- Bogovič Matijašić B, Obermajer T, Lipoglavšek L, Sernel T, Locatelli I, et al. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial. J Dairy Sci. 2016;99:5008. doi:10.3168/jds.2015-10743
- Yoon H, Park YS, Lee DH, Seo JG, Shin CM, et al. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr. 2015;57:129. doi:10.3164/jcbn.15-14
- Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014;29:52. doi:10.1111/jgh.12322
- Barbaro MR, Bianco F, Cremon C, Marasco G, Stanghellini V, et al. A Probiotic Mixture of LR 32, BL 04, and BB 536 Counteracts the Increase in Permeability Induced by the Mucosal Mediators of Irritable Bowel Syndrome by Acting on Zonula Occludens 1. Int J Mol Sci. 2025;26. doi:10.3390/ijms26062656
- Gąsiorowska A, Romanowski M, Walecka-Kapica E, Kaczka A, Chojnacki C, et al. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome-A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Med. 2024;14. doi:10.3390/jcm14010006
- Kwon H, Nam EH, Kim H, Jo H, Bang WY, et al. Effect of Lacticaseibacillus rhamnosus IDCC 3201 on irritable bowel syndrome with constipation: a randomized, double-blind, and placebo-controlled trial. Sci Rep. 2024;14:22384. doi:10.1038/s41598-024-72887-x
- Zhang L, Ni X, Jiang M, Du M, Zhang S, et al. Strains for Alleviation of Irritable Bowel Disease and Chronic Fatigue Syndrome. Microorganisms. 2024;12. doi:10.3390/microorganisms12061081
- Bonfrate L, Di Palo DM, Celano G, Albert A, Vitellio P, et al. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. Eur J Clin Invest. 2020;50:e13201. doi:10.1111/eci.13201
- Ding FCL, Karkhaneh M, Zorzela L, Jou H, Vohra S. Probiotics for paediatric functional abdominal pain disorders: A rapid review. Paediatr Child Health. 2019;24:383. doi:10.1093/pch/pxz036
- Nocerino R, Di Costanzo M, Bedogni G, Cosenza L, Maddalena Y, et al. Dietary Treatment with Extensively Hydrolyzed Casein Formula Containing the Probiotic Lactobacillus rhamnosus GG Prevents the Occurrence of Functional Gastrointestinal Disorders in Children with Cow's Milk Allergy. J Pediatr. 2019;213:137. doi:10.1016/j.jpeds.2019.06.004
- Hojsak I. Probiotics in Functional Gastrointestinal Disorders. Adv Exp Med Biol. 2019;1125:121. doi:10.1007/5584_2018_321
- Han X, Lee A, Huang S, Gao J, Spence JR, et al. Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids. Gut Microbes. 2019;10:59. doi:10.1080/19490976.2018.1479625
- Wegh CAM, Benninga MA, Tabbers MM. Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review. J Clin Gastroenterol. 2018;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017:S10. doi:10.1097/MCG.0000000000001054
- Darbaky Y, Evrard B, Patrier S, Falenta J, Garcin S, et al. Oral probiotic treatment of Lactobacillus rhamnosus Lcr35 prevents visceral hypersensitivity to a colonic inflammation and an acute psychological stress. J Appl Microbiol. 2017;122:188. doi:10.1111/jam.13320
- Cruchet S, Furnes R, Maruy A, Hebel E, Palacios J, et al. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. Paediatr Drugs. 2015;17:199. doi:10.1007/s40272-015-0124-6
- Martin FP, Cominetti O, Berger B, Combremont S, Marquis J, et al. Metabolome-associated psychological comorbidities improvement in irritable bowel syndrome patients receiving a probiotic. Gut Microbes. 2024;16:2347715. doi:10.1080/19490976.2024.2347715
- Srivastava S, Basak U, Naghibi M, Vijayakumar V, Parihar R, et al. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome. Gut Microbes. 2024;16:2338322. doi:10.1080/19490976.2024.2338322
- Lenoir M, Wienke J, Fardao-Beyler F, Roese N. An 8-Week Course of Bifidobacterium longum 35624 Is Associated with a Reduction in the Symptoms of Irritable Bowel Syndrome. Probiotics Antimicrob Proteins. 2025;17:315. doi:10.1007/s12602-023-10151-w
- Khoo XH, Chong CW, Talha AM, Philip K, Teh CS, et al. The impact of diet and ethnicity on gut microbiota variation in irritable bowel syndrome: A multi-center study. J Gastroenterol Hepatol. 2023;38:1259. doi:10.1111/jgh.16174
- Nakamura Y, Suzuki S, Murakami S, Nishimoto Y, Higashi K, et al. Integrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by BB536 supplementation: A RCT. Comput Struct Biotechnol J. 2022;20:5847. doi:10.1016/j.csbj.2022.10.026
- Yakovenko EP, Strokova TV, Ivanov AN, Iakovenko AV, Gioeva IZ, et al. [The effectiveness of a probiotic containing Bifidobacterium longum BB-46 and Enterococcus faecium ENCfa-68 in the treatment of post-infectious irritable bowel syndrome. Prospective randomized comparative study]. Ter Arkh. 2022;94:180. doi:10.26442/00403660.2022.02.201368
- Groeger D, Murphy EF, Tan HTT, Larsen IS, O'Neill I, et al. Interactions between symptoms and psychological status in irritable bowel syndrome: An exploratory study of the impact of a probiotic combination. Neurogastroenterol Motil. 2023;35:e14477. doi:10.1111/nmo.14477
- Sabaté JM, Iglicki F. Effect of 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol. 2022;28:732. doi:10.3748/wjg.v28.i7.732
- Di Pierro F, Pane M. Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin. Clin Nutr ESPEN. 2021;42:15. doi:10.1016/j.clnesp.2020.12.025
- Caviglia GP, Tucci A, Pellicano R, Fagoonee S, Rosso C, et al. Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with ES1 for 8 or 12 Weeks: A Preliminary Report. J Clin Med. 2020;9. doi:10.3390/jcm9082353
- Buhner S, Hahne H, Hartwig K, Li Q, Vignali S, et al. Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients. PLoS One. 2018;13:e0193943. doi:10.1371/journal.pone.0193943
- JanssenDuijghuijsen L, van den Belt M, Rijnaarts I, Vos P, Guillemet D, et al. Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial. Eur J Nutr. 2024;63:1983. doi:10.1007/s00394-024-03398-8
- Skrzydło-Radomańska B, Prozorow-Król B, Kurzeja-Mirosław A, Cichoż-Lach H, Laskowska K, et al. The Efficacy and Safety of Single-Strain Probiotic Formulations Containing or in Adult Patients with Irritable Bowel Syndrome-A Randomized Double-Blind Placebo-Controlled Three-Arm Interventional Trial. J Clin Med. 2023;12. doi:10.3390/jcm12144838
- Boonma P, Shapiro JM, Hollister EB, Badu S, Wu Q, et al. Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome. Front Pain Res (Lausanne). 2021;2:691689. doi:10.3389/fpain.2021.691689
- Xu H, Ma C, Zhao F, Chen P, Liu Y, et al. Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome. Eur J Nutr. 2021;60:2553. doi:10.1007/s00394-020-02437-4
- Szajewska H, Hojsak I. Health benefits of GG and subspecies BB-12 in children. Postgrad Med. 2020;132:441. doi:10.1080/00325481.2020.1731214
- Le Nevé B, Derrien M, Tap J, Brazeilles R, Cools Portier S, et al. Fasting breath H2 and gut microbiota metabolic potential are associated with the response to a fermented milk product in irritable bowel syndrome. PLoS One. 2019;14:e0214273. doi:10.1371/journal.pone.0214273
- Baştürk A, Artan R, Yılmaz A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial. Turk J Gastroenterol. 2016;27:439. doi:10.5152/tjg.2016.16301
- Eskesen D, Jespersen L, Michelsen B, Whorwell PJ, Müller-Lissner S, et al. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. Br J Nutr. 2015;114:1638. doi:10.1017/S0007114515003347
- Veiga P, Pons N, Agrawal A, Oozeer R, Guyonnet D, et al. Changes of the human gut microbiome induced by a fermented milk product. Sci Rep. 2014;4:6328. doi:10.1038/srep06328
- Yoon JY, Cha JM, Oh JK, Tan PL, Kim SH, et al. Probiotics Ameliorate Stool Consistency in Patients with Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Study. Dig Dis Sci. 2018;63:2754. doi:10.1007/s10620-018-5139-8
- Ortiz-Lucas M, Tobías A, Saz P, Sebastián JJ. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. Rev Esp Enferm Dig. 2013;105:19.
- Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol. 2012;46:220. doi:10.1097/MCG.0b013e31823712b1
- Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, et al. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28:994. doi:10.1111/j.1365-2036.2008.03818.x
- Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, et al. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol. 2008;32:147. doi:10.1016/j.gcb.2007.06.001
- Astegiano M, Pellicano R, Terzi E, Simondi D, Rizzetto M. Treatment of irritable bowel syndrome. A case control experience. Minerva Gastroenterol Dietol. 2006;52:359.
- Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol. 2001;152:735.
- Siyal M, Abbas Z, Amir MR, Qadeer MA. Saccharomyces cerevisiae for abdominal pain and discomfort in irritable bowel syndrome patients. Pak J Med Sci. 2024;40:492. doi:10.12669/pjms.40.3.8349
- Liu J, Ren H, Yuan F, Shao M, Luo H. The effects of on rat colonic hypermotility induced by repeated water avoidance stress and the potential mechanism. PeerJ. 2022;10:e14390. doi:10.7717/peerj.14390
- Mourey F, Decherf A, Jeanne JF, Clément-Ziza M, Grisoni ML, et al. I-3856 in irritable bowel syndrome with predominant constipation. World J Gastroenterol. 2022;28:2509. doi:10.3748/wjg.v28.i22.2509
- Gayathri R, Aruna T, Malar S, Shilpa B, Dhanasekar KR. Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome. Int J Colorectal Dis. 2020;35:139. doi:10.1007/s00384-019-03462-4
- Cayzeele-Decherf A, Pélerin F, Leuillet S, Douillard B, Housez B, et al. CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World J Gastroenterol. 2017;23:336. doi:10.3748/wjg.v23.i2.336
- Spiller R, Pélerin F, Cayzeele Decherf A, Maudet C, Housez B, et al. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterol J. 2016;4:353. doi:10.1177/2050640615602571
- Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, et al. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis. 2015;47:119. doi:10.1016/j.dld.2014.11.007
- Gomes P, Laroute V, Beaufrand C, Bézirard V, Aubry N, et al. Postbiotic potential of Lactococcus lactis CNCM I-5388 in alleviating visceral pain in female rat through GABA production: The innovative concept of the "active-GAD bag". FASEB J. 2025;39:e70383. doi:10.1096/fj.202401125RR
- Gomes P, Laroute V, Beaufrand C, Daveran-Mingot ML, Aubry N, et al. Lactococcus lactis CNCM I-5388 versus NCDO2118 by its GABA hyperproduction ability, counteracts faster stress-induced intestinal hypersensitivity in rats. FASEB J. 2023;37:e23264. doi:10.1096/fj.202301588R
- Laroute V, Beaufrand C, Gomes P, Nouaille S, Tondereau V, et al. NCDO2118 exerts visceral antinociceptive properties in rat via GABA production in the gastro-intestinal tract. Elife. 2022;11. doi:10.7554/eLife.77100
